IQVIA Holdings Inc. announced the pricing of a $2 billion offering of senior notes due in March 2034, bearing an interest rate of 6.375% per annum with semi-annual payments. The subsidiary intends to use the gross proceeds to fully redeem its existing Senior 5.000% Notes due 2026, repay a portion of outstanding indebtedness under its revolving credit facility, and cover related fees and expenses. The transaction is expected to close on or about September 23, 2026, subject to customary conditions. IQVIA operates in the life sciences and healthcare industries as a global provider of clinical research services, commercial insights, and healthcare intelligence.

IQVIA Holdings Inc. reported second-quarter 2026 financial results, announcing revenue of $4,368 million, an 8.7% year-over-year increase. GAAP diluted earnings per share were $1.53, while adjusted diluted EPS rose 12.1% to $3.15. The company generated $994 million in adjusted EBITDA and $558 million in operating cash flow. R&D Solutions net new bookings reached a record $3.15 billion, up 19% year-over-year. IQVIA raised its full-year 2026 guidance, projecting revenue between $17.275 billion and $17.475 billion, adjusted EBITDA between $4.0 billion and $4.05 billion, and adjusted diluted EPS between $12.80 and $13.00. The company operates in the clinical research services, commercial insights, and healthcare intelligence industry.

IQVIA Inc. completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033. The net proceeds will be used to refinance existing indebtedness and cover offering-related fees and expenses. IQVIA Holdings Inc. is a provider of advanced analytics and clinical research services for the healthcare industry.

IQVIA Holdings Inc. has authorized an additional $2,000 million for the repurchase of its common stock under its existing equity repurchase program. This increase brings the total remaining authorization for the program to $3,217 million.